Lineage Cell Therapeutics, Inc. Intangible Assets, Net (Excluding Goodwill)
Lineage Cell Therapeutics, Inc. (LCTX) had Intangible Assets, Net (Excluding Goodwill) of $31.70 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-06
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $31.70M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $31.70M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $31.70M.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $31.70M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-30 | $31.70M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $31.70M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $31.70M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $31.70M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $31.70M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $46.54M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $46.54M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $46.54M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $46.54M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $46.54M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $46.56M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $46.59M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $46.63M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $46.66M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $46.69M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $46.72M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $46.76M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $46.79M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $46.82M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $46.85M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $46.89M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $46.92M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $47.03M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $47.17M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $47.42M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $47.75M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $48.25M 10-K · filed 2021-03-11 | |
| 2016-03-31 | $32.28M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $33.59M 10-Q · filed 2016-05-10 | |
| 2015-09-30 | $34.91M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $36.22M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $37.53M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $38.85M 10-K · filed 2016-03-15 | $38.85M 10-K · filed 2015-03-11 |
| 2014-09-30 | $42.10M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $43.47M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $44.84M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $46.21M 10-K · filed 2015-03-11 | |
| 2013-09-30 | $18.56M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $19.20M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $19.84M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $20.49M 10-K · filed 2014-03-17 | |
| 2012-03-31 | $18.08M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $18.62M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $20.08M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $21.65M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $15.39M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |